
|Articles|July 15, 2004
Verteporfin launched into Japanese market
New York-Japanese patients have access to the only treatment for some forms of wet age-related macular degeneration (AMD) with the launch of verteporfin (Visudyne, QLT PhotoTherapeutics/Novartis Ophthalmics) in Japan.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















